[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Benjamin Viglianti\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100404420","early-phase-1-positron-emission-tomography-pet-imaging-of-cholesterol-trafficking-clinical-evaluation-of-18ffnp-59-in-normal-human-subjects-groups-2-3--4-100404420",false,"NCT04546126","Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)","Inclusion Criteria (Groups 2 \\& 3):\n\n* Participants without any known adrenal pathology as normal controls for undergoing endocrine manipulation\n\nExclusion Criteria (Groups 2 \\& 3):\n\n* Pregnancy\n* Unable to do imaging\n* Body weight greater than 400 lbs (181 Kg)\n* Prisoners are not eligible\n* Subjects unable to provide own consent are not eligible\n* Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)\u002F Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues.\n* Known adrenal pathology\n\nInclusion Criteria (Group 4):\n\n* Abnormal adrenal cortical hormone secretion\n\nExclusion Criteria (Group 4):\n\n* Pregnant",true,"ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\\[18F\\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.",[26,27,28],"Radiotracer","Hypertension","Cholesterol","RECRUITING","2025-11-27",{"date":32,"type":33},"2025-12-05","ACTUAL",{"date":35,"type":33},"2021-11-01",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Benjamin Viglianti","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":57},"100403376","early-phase-1-positron-emission-tomography-pet-imaging-of-cholesterol-trafficking-clinical-evaluation-of-18ffnp-59-in-normal-human-subjects-group-1-100403376","NCT04532489","Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)","Inclusion Criteria:\n\n* Participants without any known adrenal pathology as normal controls for radiation dosimetry purposes\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to do imaging\n* Body weight greater than 400 lbs (181 Kg)\n* Prisoners are not eligible\n* Subjects unable to provide own consent are not eligible\n* Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)\u002F Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues.\n* Known adrenal pathology",{"count":48,"type":20},6,[23],"This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\\[18F\\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \\[18F\\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.",[26,27,28],{"date":32,"type":33},{"date":54,"type":33},"2021-01-18",{"date":37,"type":20},{"name":39,"class":40},1,""]